You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Rituxan

Showing 1 - 25 of 789
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Hairy Cell Leukemia Trial run by the NCI (Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience)

Active, not recruiting
  • Hairy Cell Leukemia
  • Moxetumomab Pasudotox-tdfk
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)

Active, not recruiting
Has Results
  • Waldenstrom's Macroglobulinemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 5, 2022

Mantle Cell Lymphoma Trial in United States (lenalidomide, rituximab)

Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • Tampa, Florida
  • +3 more
Mar 26, 2022

Rheumatoid Arthritis Trial (CT-P10, Rituxan, MabThera)

Completed
Has Results
  • Rheumatoid Arthritis
  • CT-P10
  • +2 more
  • (no location specified)
Nov 18, 2021

Lymphoma Trial in Houston (Ibritumomab Tiuxetan (Zevalin), Rituximab)

Completed
Has Results
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 30, 2022

Graft Vs Host Disease Trial in Atlanta (Rituximab, Ibrutinib)

Recruiting
  • Graft Vs Host Disease
  • Atlanta, Georgia
    Northside Hospital
Oct 19, 2022

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

Interstitial Lung Disease, Scleroderma Trial in Assiut (Rituximab, IL6 inhibitor)

Completed
  • Interstitial Lung Disease
  • Scleroderma
  • Assiut, Yes, Egypt
    Manal Hassanien
Jul 18, 2023

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Rheumatoid Arthritis Trial (MabionCD20 (candidate biosimilar to rituximab), MabThera®, Rituxan®)

Not yet recruiting
  • Rheumatoid Arthritis
  • MabionCD20 (candidate biosimilar to rituximab)
  • +2 more
  • (no location specified)
Sep 17, 2021

Post-transplant Lymphoproliferative Disorder Trial in Saint Louis (Polatuzumab vedotin, Rituximab, CHP)

Not yet recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Polatuzumab vedotin
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Sep 9, 2023

Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma Trial run by the NCI (Interferon, Rituxan and

Recruiting
  • Lymphomatoid Granulomatosis
  • +3 more
  • Interferon
  • Rituxan and EPOCH
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)

Not yet recruiting
  • Follicular Lymphoma
  • Low Grade Non-Hodgkin's Lymphoma, Adult
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)

Active, not recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Jan 16, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Obinutuzumab, Rituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Dec 5, 2022

Chronic Lymphocytic Leukemia Trial in Washington, Hackensack (Venetoclax, Rituximab, Rituximab/Hyaluronidase Human)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Washington, District of Columbia
  • +1 more
Mar 14, 2022

Anemia, Sickle Cell Trial in New York (Siplizumab, Exchange Transfusion, Total Body Irradiation)

Recruiting
  • Anemia, Sickle Cell
  • New York, New York
    Columbia University Irving Medical Center
Oct 9, 2023

Lung Transplant Trial in United States (Rituximab (Rituxan®), Placebo)

Completed
Has Results
  • Lung Transplant
  • Rituximab (Rituxan®)
  • Placebo
  • Palo Alto, California
  • +6 more
Oct 7, 2021

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)

Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 2, 2022

Lymphoma Trial in Houston (2CdA, Cyclophosphamide, Rituximab)

Completed
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 3, 2022

IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral Trial in Boston (Acalabrutinib, Rituximab)

Recruiting
  • IgM MGUS
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 14, 2022

Primary Membranous Nephropathy Trial (SNP-ACTH (1-39) Gel, Rituximab)

Not yet recruiting
  • Primary Membranous Nephropathy
  • (no location specified)
Jan 13, 2023